NSE: KOVAI · BSE: 523323 · ISIN INE177F01017
Kovai Medical Center & Hospital Limited stock analysis
Kovai Medical Center & Hospital Limited ranks #616 in the TickerSutra evidence-ranked universe with a score of 62/100 and 95% data confidence. The latest captured fundamentals show ROCE of 22.6%, quarterly sales growth of 15.3% and quarterly profit growth of 20.7%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 22.6%
- Strong CFO/EBITDA of 0.81×
- 15.9% three-year sales CAGR
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- No calculated threshold risk in the current snapshot.
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹905cr | ₹261cr | ₹104cr | 29.0% |
| 2023 | ₹1,020cr | ₹274cr | ₹116cr | 27.0% |
| 2024 | ₹1,220cr | ₹346cr | ₹180cr | 28.0% |
| 2025 | ₹1,371cr | ₹390cr | ₹209cr | 28.0% |
| 2026 | ₹1,586cr | ₹445cr | ₹244cr | 28.0% |
| TTM | ₹1,644cr | ₹458cr | ₹256cr | 28.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
We enclose herewith the voting results of postal ballot for the Re-designation of Dr.Arun N Palaniswami, Executive Director as Joint Managing Director of the Company.
RoutineKovai Medical Center & Hospital Ltd - 523323 - Closure of Trading WindowBSE · 19 Sept 2026The trading window for trading in Company''s securities shall remain closed from 01st October,2026 till the end of 48 hours after the declaration of Un-audited Financial results for the ....
MANAGEMENT COMMENTARY
Signals from filed documents
Focusing on sta- ble and larger mar- kets. Strengthening regulatory capaci - ty hence mitigating risks from external sources. Positive: Compliance with relevant regulatory require- ments pertaining to the ESG domain reflects the Compa - ny’s commitment towards re- sponsible business practices.
During the year 2025-26, no complaints were received by the Company related to sexual harassment. RELATED PARTY TRANSACTIONS AND POLICY ON RELATED PARTY TRANSACTIONS All transactions with Related Parties are at arm’s length and in the ordinary course of business duly approved by the Audit Committee of the Board. Hence there are no transactions which are either not in arm’s length or which are material in nature requi
However, this number does not include the large Shareholders i.e. Shareholders holding 2% or more shareholding, Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…